| First Author | Soccio RE | Year | 2014 |
| Journal | Cell Metab | Volume | 20 |
| Issue | 4 | Pages | 573-91 |
| PubMed ID | 25242225 | Mgi Jnum | J:215534 |
| Mgi Id | MGI:5605598 | Doi | 10.1016/j.cmet.2014.08.005 |
| Citation | Soccio RE, et al. (2014) Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 20(4):573-91 |
| abstractText | Type 2 diabetes is caused by insulin resistance coupled with an inability to produce enough insulin to control blood glucose, and thiazolidinediones (TZDs) are the only current antidiabetic agents that function primarily by increasing insulin sensitivity. However, despite clear benefits in glycemic control, this class of drugs has recently fallen into disuse due to concerns over side effects and adverse events. Here we review the clinical data and attempt to balance the benefits and risks of TZD therapy. We also examine potential mechanisms of action for the beneficial and harmful effects of TZDs, mainly via agonism of the nuclear receptor PPARgamma. Based on critical appraisal of both preclinical and clinical studies, we discuss the prospect of harnessing the insulin sensitizing effects of PPARgamma for more effective, safe, and potentially personalized treatments of type 2 diabetes. |
